Blood Donation From Warfarin Users for the Development of POC INR Monitor

Not Applicable

• Conditions: Atrial Fibrillation; Pulmonary Embolism; Deep Vein Thrombosis
• Interventions: Procedure: Venepuncture

• Registration Number: NCT02355730
• Lead Sponsor: Microvisk Technologies Ltd

Brief Summary

This study is to further develop and optimise the design and manufacturing process of a handheld device to monitor and manage Warfarin (blood thinning anticoagulation drug) therapy. The device comprises of a handheld instrument and a disposable test strip and reports how blood coagulation is working in terms of standardised units called International Normalised Ratio (INR). A single drop of fresh whole blood and plasma will be added to the strip and the INR result displayed on the instrument. Blood samples are to be collected from patients attending a hospital based INR clinic who are on Warfarin Therapy. The samples are to be used in a series of experiments in the laboratory to test the Microvisk POC INR Monitors accuracy, precision, stability and robustness.

Detailed Description

The number of patients receiving anticoagulation therapy with warfarin and other vitamin K antagonists has been rising in recent years. Increasing life expectancy is increasing the proportion of the population having conditions such as Atrial Fibrillation and venous thrombosis, where primary and secondary prevention of thromboembolic complications are best achieved with anticoagulation.

Unpredictable pharmacokinetics, widespread interactions with drugs and food and the narrow therapeutic window make closely monitoring Vitamin K antagonists a necessity. Portable point of care (POC) coagulometers which measure PT from capillary whole blood and provide an INR reading within a few minutes are already widely available throughout North American and Europe. They give comparable results when compared to laboratory based systems are popular with patients and significantly shorten the duration of clinics. In addition, the United Kingdom Department of Health has been encouraging the use of anticoagulation services in Primary Care Trusts the aim being to provide INR monitoring in community clinics and General Practice surgeries relieving pressure on hospital services and reducing inconvenience for patients.

Although coagulometers are now commercially available the Microvisk INR Testing System has been designed to have advantages, particularly in terms of test robustness, user comfort, ease of use and reduction of user error. The present trial has been designed to develop the second generation Microvisk INR Test System; blood samples will also be used to optimise manufacturing processes and verify the quality of Test Strip Lots.

Study Timeline

• Study Start: 2014-05
• Status Verified: 2015-01
• Study First Submitted: 2015-01-16
• Study First Submitted QC: 2015-01-30
• Last Update Submitted: 2015-01-30
• Study First Posted: 2015-02-04
• Last Update Posted: 2015-02-04
• Primary Completion: 2016-05
• Study Completion: 2016-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1560

Inclusion Criteria

1. Subject is male or female, greater than 18 years of age
2. Subject is receiving warfarin (or warfarin-like) therapy as part of their clinical care
3. Subject is informed and has been given ample time and opportunity to think about his/her participation and has given his/her written informed consent

Exclusion Criteria

1. Subjects aged <18 years of age
2. Subjects who are unable to give written consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Warfarin Patients	Venepuncture	Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy

Primary Outcome Measures

Name	Time	Method
The Primary Outcome will be measured in terms of differences in International Normalised Ratio when the Generation 2 system is tested against the Generation 1 system using the blood samples from the same donors.	2 years	The Primary Outcome will be measured in terms of differences in International Normalised Ratio when the Generation 2 system is tested against the Generation 1 system using the blood samples from the same donors. Those differences will be reported in terms of accuracy, precision and sensitivity to interferents.

Secondary Outcome Measures

Name	Time	Method
The Secondary Outcome will be measured in terms of differences in International Normalised Ratio when the Generation 2 system is tested against the International Standard Method using the blood samples from the same donors.	2 years	A master batch of test strips will be calibrated against an International Reference Preparation (rTF/09) thromboplastin. The accuracy of the master batch will be verified using patient samples.

Trial Locations

Locations (1)

Royal Liverpool & Broadgreen University Hospital NHS Trust; 🇬🇧 Liverpool, Merseyside, United Kingdom